Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Aurinia Pharmaceuticals stock | $14.25

Own Aurinia Pharmaceuticals stock in just a few minutes.


Fact checked

Aurinia Pharmaceuticals Inc is a biotechnology business based in the US. Aurinia Pharmaceuticals shares (AUPH) are listed on the NASDAQ and all prices are listed in US Dollars. Aurinia Pharmaceuticals employs 62 staff and has a trailing 12-month revenue of around USD$318,000.

How to buy shares in Aurinia Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Aurinia Pharmaceuticals Find the stock by name or ticker symbol: AUPH. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aurinia Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$14.25, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Aurinia Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Aurinia Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Aurinia Pharmaceuticals share price

Use our graph to track the performance of AUPH stocks over time.

Aurinia Pharmaceuticals shares at a glance

Information last updated 2020-09-25.
Latest market closeUSD$14.25
52-week rangeUSD$3.52 - USD$21.93
50-day moving average USD$14.3754
200-day moving average USD$15.0362
Wall St. target priceUSD$11.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.697

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Available asset types Stock trade fee Option trade fee Annual fee
Stocks,Mutual funds,ETFs,Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
TD Ameritrade
Stocks,Bonds,Options,Mutual funds,ETFs,Forex,Futures
or $25 If it is broker-assisted
$0 + $0.65/contract,
or $25 Broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Interactive Brokers
Stocks,Bonds,Options,Mutual funds,Index funds,ETFs,Forex,Futures,Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aurinia Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aurinia Pharmaceuticals price performance over time

Historical closes compared with the close of $14.25 from 2020-09-25

1 week (2020-09-22) -3.85%
1 month (2020-08-28) 3.49%
3 months (2020-06-29) -6.25%
6 months (2020-03-27) -0.77%
1 year (2019-09-27) 161.47%
2 years (2018-09-28) 114.61%
3 years (2017-09-29) 127.27%
5 years (2015-09-29) 410.75%

Aurinia Pharmaceuticals financials

Revenue TTM USD$318,000
Gross profit TTM USD$-52,548,000
Return on assets TTM -27.23%
Return on equity TTM -77.6%
Profit margin 0%
Book value $2.121
Market capitalisation USD$1.8 billion

TTM: trailing 12 months

Shorting Aurinia Pharmaceuticals shares

There are currently 4.4 million Aurinia Pharmaceuticals shares held short by investors – that's known as Aurinia Pharmaceuticals's "short interest". This figure is 6.1% up from 4.1 million last month.

There are a few different ways that this level of interest in shorting Aurinia Pharmaceuticals shares can be evaluated.

Aurinia Pharmaceuticals's "short interest ratio" (SIR)

Aurinia Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aurinia Pharmaceuticals shares currently shorted divided by the average quantity of Aurinia Pharmaceuticals shares traded daily (recently around 1.2 million). Aurinia Pharmaceuticals's SIR currently stands at 3.64. In other words for every 100,000 Aurinia Pharmaceuticals shares traded daily on the market, roughly 3640 shares are currently held short.

However Aurinia Pharmaceuticals's short interest can also be evaluated against the total number of Aurinia Pharmaceuticals shares, or, against the total number of tradable Aurinia Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aurinia Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Aurinia Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Aurinia Pharmaceuticals shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aurinia Pharmaceuticals.

Find out more about how you can short Aurinia Pharmaceuticals stock.

Aurinia Pharmaceuticals share dividends

We're not expecting Aurinia Pharmaceuticals to pay a dividend over the next 12 months.

Have Aurinia Pharmaceuticals's shares ever split?

Aurinia Pharmaceuticals's shares were split on a 1:50 basis on 23 October 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aurinia Pharmaceuticals shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Aurinia Pharmaceuticals shares which in turn could have impacted Aurinia Pharmaceuticals's share price.

Aurinia Pharmaceuticals share price volatility

Over the last 12 months, Aurinia Pharmaceuticals's shares have ranged in value from as little as $3.52 up to $21.93. A popular way to gauge a stock's volatility is its "beta".

AUPH.US volatility(beta: 0.98)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aurinia Pharmaceuticals's is 0.9797. This would suggest that Aurinia Pharmaceuticals's shares are less volatile than average (for this exchange).

Aurinia Pharmaceuticals overview

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.

Frequently asked questions

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site